This is only compatible with IE 8 and later, so browse at your own risk or upgrade.Internet Explorer: IE8 以 推 奨 そ れ 以前 ブ ウ ザ を ご 使用 方 は 最 版 に プ グ て く だ さ。
M / CLOUDED
Fujifilm Diosynth Biotechnologies, a unit of Fujifilm Corp.de Japan, announced Monday that it will manufacture the candidate vaccine for coronavirus from Novavax Inc., United Kingdom, early next year.
Fujifilm Diosynth Biotechnologies will produce up to 60 million doses of the COVID-19 candidate vaccine, developed through the US biotechnology company, for origin in the UK in Billingham.
Billingham is capable of generating up to 180 million doses consistent with the year.Fujifilm Diosynth Biotechnologies plans to supply the candidate vaccine to other countries.
Production in Britain comes after Fujifilm Diosynth Biotechnologies recently began producing the candidate vaccine at a site in North Carolina for use in a clinical trial involving up to 30,000 subjects in the United States, which is expected to start in the fall.
Since the early stages of the COVID-19 crisis, the Japan Times has provided free access to very important data on the effect of the new coronavirus, as well as practical data on how to deal with the pandemic.today so that we can continue to provide you with up-to-date and detailed data on Japan.
The Japan Times LTD. All rights are reserved.